Immune Deficiency Does Not Increase Inflatable Penile Prosthesis Reoperation Rates.

Complication Immunocompromised Immunodeficiency Infection Inflatable Penile Prosthesis Reoperation Replacement Revision Solid-Organ Transplant

Journal

The journal of sexual medicine
ISSN: 1743-6109
Titre abrégé: J Sex Med
Pays: Netherlands
ID NLM: 101230693

Informations de publication

Date de publication:
08 2021
Historique:
received: 01 02 2021
revised: 11 05 2021
accepted: 14 06 2021
pubmed: 26 7 2021
medline: 21 8 2021
entrez: 25 7 2021
Statut: ppublish

Résumé

Immunocompromised patients are postulated to have higher rates of post-operative infection. We sought to determine if inflatable penile prosthesis (IPP) reoperation rates (due to infection, erosion, device malfunction or patient dissatisfaction) are higher among immunocompromised men. We analyzed men who underwent initial IPP insertion from 2000 to 2016 in the New York Statewide Planning and Research Cooperative System database. Immunocompromised patients were propensity-score matched in a 1:3 fashion with immunocompetent patients. We estimated and compared reoperation rates (including removal, reoperation due to infection, revision, or replacement of an IPP after an index procedure) at 30 days, 90 days, 1 year and 3 years of follow up between immunocompromised men and controls by performing a Kaplan Meier analysis and Log-rank tests. Cox proportional hazards models were built to examine the overall association between immune deficient status and the risk of reoperation. Reoperation rate and time to reoperation after index IPP placement. A total of 245 immunocompromised patients who received an initial IPP between 2000 and 2016 were identified. After propensity score matching, we analyzed 235 immunocompromised men and 705 controls. There was no difference in overall reoperation rates between immunocompromised men and controls within any time period assessed (30 days, 90 days, 1 year, or 3 years). In our Cox proportional hazards model, the hazards of overall reoperation, removal, or revision/replacement (HR 1.11 [95% CI 0.74-1.67], HR 1.58 [95% CI 0.90-2.79)], and HR 0.83 [95% CI 0.47-1.45], respectively) were not significant different between immunocompromised men and controls. Reoperation due to infection was also not significantly different between immunocompromised and immunocompetent men (HR 2.06 [95% CI 0.97-4.40]). This study is strengthened by its size as the largest cohort of immunocompromised men treated with IPP to date in the literature, but is limited by the retrospective nature of the database which may introduce selection bias and by the low event rate for IPP reoperation. Reoperation rates, including those due to infection, are not significantly different between immunocompromised men and immunocompetent controls. Therefore, immune status in appropriately selected candidates does not appear to place patients at substantially higher risk of explant or revision. Gaffney CD, Fainberg J, Aboukhshaba A, et al. Immune Deficiency Does Not Increase Inflatable Penile Prosthesis Reoperation Rates. J Sex Med 2021;18:1427-1433.

Identifiants

pubmed: 34303632
pii: S1743-6095(21)00530-0
doi: 10.1016/j.jsxm.2021.06.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1427-1433

Informations de copyright

Copyright © 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Christopher D Gaffney (CD)

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Jonathan Fainberg (J)

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Nahid Punjani (N)

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Ahmad Aboukhshaba (A)

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Hudson Pierce (H)

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Neal Patel (N)

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Xinyan Zheng (X)

Department of Population Health Science, New York, NY, USA.

Tianyi Sun (T)

Department of Population Health Science, New York, NY, USA.

Art Sedrakyan (A)

Department of Population Health Science, New York, NY, USA.

James A Kashanian (JA)

Department of Urology, Weill Cornell Medicine, New York, NY, USA. Electronic address: jak9111@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH